Principle Wealth Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Principle Wealth Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,772	Closed	-$326K	–	322
2021 Q2	$326K	Hold	1,772	–	–	0.04%	242
2021 Q1	$271K	Hold	1,772	–	–	0.03%	249
2020 Q4	$277K	Buy	+1,772	New	+$228K	0.04%	232
2020 Q3	–	Sell	-1,672	Closed	-$188K	–	468
2020 Q2	$188K	Buy	+1,672	New	+$178K	0.06%	156
2019 Q3	–	Sell	-1,672	Closed	-$219K	–	171
2019 Q2	$219K	Hold	1,672	–	–	0.11%	128
2019 Q1	$226K	Buy	+1,672	New	+$208K	0.13%	116

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Principle Wealth Partners's ALXN Position: Q3 2021 in Review

Principle Wealth Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,772 shares — an estimated $326K sold.

Principle Wealth Partners first reported a position in ALXN in Q1 2019 and held it in 6 quarters. The position peaked at $326K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Principle Wealth Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Principle Wealth Partners sold 1,772 Alexion Pharmaceuticals shares in Q3 2021, an estimated $326K.
Principle Wealth Partners first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 6 quarters.
Principle Wealth Partners's Alexion Pharmaceuticals position peaked at $326K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Principle Wealth Partners's 13F filing for Q3 2021, filed 16 Nov 2021.